当前位置:主页 > 肿瘤疾病 > 文章内容

2026 亚太胃食管癌大会共识:中低患病率地区早期发现非贲门胃癌

作者:中华医学网发布时间:2026-11-08 15:32浏览: 次

2026 APAGE Consensus: Screening Strategies for Early Detection of Non‑Cardia Gastric Cancer in Intermediate‑ and Low‑Prevalence Regions

APAGE:Asia-Pacific Gastric and Esophageal Cancer Group 亚太胃食管癌协作组 适用范围:非贲门胃癌(NCGC);中低患病率地区(定义:年龄标化胃癌发病率 ASR <20/10 万 / 年);区别于韩国、日本等高发病率国家的全民胃镜筛查模式;目标:平衡检出收益、成本、内镜负荷、假阳性与过度诊疗。 核心共识总原则:不推荐全人群胃镜筛查;采用风险分层优先、高危人群靶向筛查;以风险预测模型驱动,而非单纯年龄一刀切;优先识别幽门螺杆菌(Hp)感染这一核心可干预病因。

Preface

Gastric cancer remains a major cancer burden in Asia, but incidence varies sharply across regions. High‑burden countries (Japan, South Korea) have established nationwide endoscopic screening programs. However, most Asia‑Pacific nations and subregions are intermediate‑ or low‑prevalence settings, where universal endoscopy is not cost‑effective and overwhelms local endoscopic capacity. Non‑cardia gastric cancer is strongly linked to Helicobacter pylori infection, atrophic gastritis, intestinal metaplasia, and family history. This consensus aims to provide a practical, resource‑adapted screening framework for NCGC, integrating risk scoring, non‑invasive testing, selective endoscopy, and Hp eradication as primary prevention.

1. Definition of Prevalence Strata

  • High prevalence: ASR ≥20/100,000 person‑years
  • Intermediate prevalence: ASR 10–19.9/100,000 person‑years
  • Low prevalence: ASR <10/100,000 person‑years

Note: Regional sub‑stratification is encouraged; even within a country, some counties/ethnic groups may be intermediate‑risk while others are low‑risk. Screening policy should follow local registry data, not national averages.

2. Core Risk Factors for Non‑Cardia Gastric Cancer (used in risk models)

Mandatory variables for validated risk prediction tools:

  1. Helicobacter pylori infection status (strongest modifiable driver)
  2. Age
  3. First‑degree family history of gastric cancer
  4. History of atrophic gastritis / intestinal metaplasia / dysplasia
  5. Smoking
  6. High‑salt, preserved food intake; low fresh fruit/vegetable intake

Optional variables (for refined models): male sex, heavy alcohol consumption, serum pepsinogen, gastrin‑17.

3. Recommended Screening Pathway (stepwise, tiered)

Step 1: Risk stratification (first gate)

All adults aged ≥40 years are invited for risk assessment.

  • Low risk: No further screening; lifestyle counselling; repeat risk assessment every 5 years.
  • Intermediate risk: Non‑invasive biomarker testing (Hp test ± pepsinogen panel).
  • High risk: Direct referral for upper gastrointestinal endoscopy.

The consensus recommends validated Asian gastric cancer risk scores (e.g., GCRS, modified Chinese gastric cancer risk score) rather than Western models.

Step 2: Non‑invasive testing panel for intermediate‑risk persons

Preferred combination:

  1. Hp test: urea breath test (¹³C/¹⁴C) or stool antigen test; serology is acceptable for population screening but cannot distinguish active from past infection.
  2. Serum pepsinogen (PG I/PG II ratio + PG I): marker for corpus atrophy.
  • If Hp positive OR atrophy marker abnormal → proceed to endoscopy.
  • If Hp negative + normal pepsinogen → repeat risk assessment + non‑invasive testing in 3–5 years.

Step 3: Endoscopy (gold standard confirmatory test)

  • Endoscopy is not a first-line population test in intermediate/low prevalence areas.
  • Quality assurance requirements: high‑definition white light endoscopy; narrow‑band imaging (NBI) available for suspicious lesions; systematic biopsy protocol for atrophy, metaplasia and visible lesions.
  • Biopsy protocol: mapped biopsies according to OLGA/OLGIM staging for patients with atrophic gastritis/metaplasia.
  • Chromoendoscopy is optional, not mandatory in resource‑limited settings.

4. Surveillance intervals after endoscopic findings

  1. Normal mucosa / non‑atrophic gastritis: routine population pathway, no short‑interval surveillance.
  2. OLGA I–II / mild intestinal metaplasia: endoscopy every 3–5 years.
  3. OLGA III–IV / extensive intestinal metaplasia: endoscopy every 1–2 years.
  4. Low‑grade dysplasia: endoscopy within 6–12 months.
  5. High‑grade dysplasia / early gastric cancer: endoscopic resection (ESD/EMR); follow‑up endoscopy per post‑resection protocol.

Important: Isolated focal intestinal metaplasia without atrophy does not require frequent surveillance.

5. Helicobacter pylori eradication as primary prevention (ranked high priority)

  1. Hp eradication is primary prevention, not a substitute for screening in persons already with atrophy/metaplasia.
  2. In Hp‑positive individuals without atrophy: eradication therapy reduces incident gastric cancer risk; post‑eradication confirmation is recommended.
  3. Hp eradication after established atrophy/metaplasia cannot completely reverse cancer risk, so these patients still enter endoscopic surveillance.
  4. Consensus statement: Screening and eradication programs should be paired; “screen without treat” is discouraged.

6. Special high‑risk subgroups that bypass general risk scoring

These groups go directly to endoscopic evaluation regardless of routine risk score:

  • First‑degree relative with gastric cancer (especially diagnosed <50 y)
  • Personal history of gastric dysplasia or early gastric cancer
  • Inherited gastric cancer syndromes (CDH1, etc.)
  • Persistent unexplained iron‑deficiency anaemia, chronic dyspepsia with alarm symptoms (weight loss, dysphagia, vomiting, melena)

Alarm symptoms are diagnostic workup, not population screening.

7. Rejected strategies (not recommended for intermediate/low prevalence regions)

  1. Universal upper endoscopy for all adults ≥40/50 years old
  2. Mass screening using only serum pepsinogen without Hp testing
  3. Using serum tumor markers (CEA, CA72‑4, CA19‑9) as screening tools
  4. Using barium meal radiography as primary screening test
  5. Routine screening for cardia cancer within this non‑cardia screening pathway (cardia cancer has distinct risk profile and is not covered)

8. Implementation and health‑system considerations

  1. Endoscopy capacity is the main bottleneck; tiered strategy protects endoscopy resources for high‑yield individuals.
  2. Training on gastritis staging (OLGA/OLGIM) and early lesion recognition is essential for endoscopists.
  3. Registry linkage: screening participants should be linked to cancer registry to monitor program performance (cancer detection rate, stage distribution, interval cancer rate).
  4. Cost‑effectiveness metrics to monitor: number needed to scope (NNS) to detect one early gastric cancer; proportion of screen‑detected cancers at stage I.
  5. Equity: priority access for rural, disadvantaged groups with high Hp prevalence.

9. 2026 New Consensus Updates

  1. Formal separation of non‑cardia gastric cancer screening from cardia/gastroesophageal junction cancer; separate strategies are needed for junctional tumours.
  2. Risk‑score first paradigm is upgraded to a strong recommendation for intermediate/low‑burden Asia‑Pacific settings.
  3. Clarified that pepsinogen testing is an adjunct, not a standalone triage tool.
  4. Emphasized that Hp eradication is a population prevention intervention, not a surveillance substitute for atrophy/metaplasia.
  5. Proposed regional threshold benchmarks: target NNS <200 for acceptable screening programs; NNS above 300 suggests the program is low‑yield and should be re‑calibrated.
  6. Warning against over‑surveillance for limited, low‑grade intestinal metaplasia.

10. Summary

For intermediate‑ and low‑prevalence Asia‑Pacific regions, mass endoscopic screening is not recommended. The preferred model is risk assessment → non‑invasive Hp + atrophy biomarker triage → selective endoscopy for positives. Hp test‑and‑treat is the foundational primary prevention measure. Surveillance frequency is guided by OLGA/OLGIM atrophy staging. Program governance should track early‑stage detection rate and endoscopic workload to avoid over‑screening and over‑surveillance.

Citation

Asia-Pacific Gastric and Esophageal Cancer Group (APAGE). 2026 APAGE consensus: Screening strategies for early detection of non‑cardia gastric cancer in intermediate‑ and low‑prevalence regions. Gastric Cancer, 2026.